The SABRE Trial of Hypertonic Saline in Acute Bronchiolitis

This study is currently recruiting participants.
Verified October 2011 by Sheffield Children's NHS Foundation Trust
Sponsor:
Collaborator:
University of Sheffield
Information provided by (Responsible Party):
Sheffield Children's NHS Foundation Trust
ClinicalTrials.gov Identifier:
NCT01469845
First received: November 9, 2011
Last updated: NA
Last verified: October 2011
History: No changes posted

November 9, 2011
November 9, 2011
October 2011
May 2012   (final data collection date for primary outcome measure)
Time to 'fit for discharge', which will be judged to be when the infant is feeding adequately [taking >75% of usual intake] and has been in air with a saturation of at least 92% for 6 hours, to reflect clinical practice. [ Designated as safety issue: No ]
Same as current
No Changes Posted
  • Actual time to discharge [ Designated as safety issue: No ]
  • Readmission [ Time Frame: Within 28 days from randomisation ] [ Designated as safety issue: Yes ]
  • health care utilisation [ Time Frame: post-discharge and within 28 days from randomisation ] [ Designated as safety issue: Yes ]
  • duration of respiratory symptoms [ Time Frame: post discharge and within 28 days from randomisation ] [ Designated as safety issue: Yes ]
  • Infant and parental quality of life using the Infant Toddler Quality of Life (ITQoL) questionnaire [ Time Frame: 28 days following randomisation. ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
The SABRE Trial of Hypertonic Saline in Acute Bronchiolitis
Hypertonic Saline in Acute Bronchiolitis: Randomised Controlled Trial and Economic Evaluation

Acute bronchiolitis is a common, distressing illness affecting children. A virus infects the lungs, and then the airways become blocked, leading to difficulties with breathing. It is the most common reason why children are admitted to hospital, with 1-3% of all children admitted to hospital during their first winter, creating enormous strains on NHS services. The majority of those admitted with the condition are under six months of age and the associated stress for parents is considerable. After forty years of research the best treatment we have is supportive care and oxygen.

Recent research suggests that salt water, sprayed as a mist so that the children can breathe it in ('nebulised 3% hypertonic saline') might help children with acute bronchiolitis. Scientists think that the salt water changes the mucus which blocks the airways so that it can be cleared more easily. Three small research studies all suggested that a child's time in hospital could be reduced by a quarter by using this treatment. If this was true, it would be good for children, their families and the children's wards trying to cope with the large numbers admitted with bronchiolitis every year.

To decide whether this treatment should be used throughout the NHS, we need to run a randomised controlled trial of hypertonic saline in a large number of children. The trial will tell us if adding saline to usual care reduces distress in both children and parents, as well as whether it reduces the length of time they stay in hospital. We will then know if the treatment is the best thing for children with bronchiolitis and whether it provides the NHS with good value for money.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Acute Bronchiolitis
Device: 3% hypertonic saline
4 ml dose to be administered every 6 hours
Other Name: mucoclear 3%
  • Active Comparator: hypertonic saline and usual care
    Intervention: Device: 3% hypertonic saline
  • Active Comparator: usual care (oxygen therapy)
    Intervention: Device: 3% hypertonic saline
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
300
December 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Previously healthy infants under 1 year of age
  • Admitted to hospital with a clinical diagnosis of acute bronchiolitis, following the UK definition of an infant with an apparent viral respiratory tract infection associated with airways obstruction manifest by hyperinflation, tachypnoea and subcostal recession with widespread crepitations on auscultation
  • Requiring supplemental oxygen therapy on admission

Exclusion Criteria:

  • Wheezy bronchitis or asthma - children with an apparent viral respiratory infection and wheeze with no or occasional crepitations
  • Previous lower respiratory tract infections
  • Risk factors for severe disease [gestation <32 weeks, immunodeficiency, neurological and cardiac conditions, chronic lung disease]
  • Subjects where the carer's English is not fluent and translational services are not available
  • Requiring admission to high dependency or intensive care units at the time of recruitment
Both
up to 12 Months
Yes
Contact: Mark L Everard, DM 0044 114 271 7400 m.l.everard@sheffield.ac.uk
Contact: Liz A Cross, MA 0044 114 222 0762 e.a.cross@sheffield.ac.uk
United Kingdom
 
NCT01469845
SCH/1/016, HTA09/91/22
Yes
Sheffield Children's NHS Foundation Trust
Sheffield Children's NHS Foundation Trust
University of Sheffield
Not Provided
Sheffield Children's NHS Foundation Trust
October 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP